Kyverna Therapeutics, Inc. (KYTX)
| Market Cap | 177.87M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -110.66M |
| Shares Out | 43.17M |
| EPS (ttm) | -3.99 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 264,078 |
| Open | 4.200 |
| Previous Close | 4.080 |
| Day's Range | 4.050 - 4.340 |
| 52-Week Range | 4.050 - 30.600 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 23.20 (+463.11%) |
| Earnings Date | Nov 13, 2024 |
About KYTX
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for KYTX stock is "Buy." The 12-month stock price forecast is $23.2, which is an increase of 463.11% from the latest price.
News
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024
Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis (LN) Treated With KYV-101 Target Dose KYV-101 Treatment Continues to Demonstrate Robus...
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development Progra...
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeuti...
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024
Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple sclerosis reinforcing KYV-101's initial efficacy and safety profile and broad po...
Kyverna Therapeutics Announces Leadership Update
– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launche...
Kyverna Therapeutics, Inc. May Have Committed Securities Fraud And The Schall Law Firm Encourages Shareholders To Join An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Ther...
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Violated Securities Laws And Investors Are Invited To Participate
LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Ther...
Shareholders With Losses In Kyverna Therapeutics, Inc. Should Contact The Schall Law Firm About A Securities Fraud Investigation
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera...
Kyverna Therapeutics Inc May Have Violated Securities Regulations And The Schall Law Firm Invites Investors To Join An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera...
Shareholders In Kyverna Therapeutics, Inc. Are Urged To Partake In The Schall Law Firm's Securities Related Investigation
LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera...
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Investors Should Join The Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera...
Kyverna Therapeutics Inc. May Have Violated Securities Regulations And The Schall Law Firm Wants Stakeholders With Losses To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera...
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Committed Securities Fraud And Impacted Investors Are Urged To Play A Part
LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera...
Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says
Adobe shares are up 31% over the past three months, having rallied after a strong quarterly earnings report that highlighted strong demand for the software developer's AI products.
Kyverna Therapeutics Inc. May Be Liable To Compensate Investors And Those With Losses Should Contact The Schall Law Firm About An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera...
The Schall Law Firm Wants The Public's Contributions To An Investigation Into Whether Kyverna Therapeutics Inc Committed Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Thera...
Kyverna Therapeutics Inc. Is Being Looked Into For Committing Securities Law Infractions And Stakeholders Are Invited To Help The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape...
A Securities Fraud Inquiry Has Been Launched Into Kyverna Therapeutics Inc And The Schall Law Firm Is Seeking Investor Participation
LOS ANGELES, CA / ACCESSWIRE / August 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape...
The Schall Law Firm Is Investigating Whether Kyverna Therapeutics Inc. Violated Securities Laws And Shareholders Are Urged To Reach Out
LOS ANGELES, CA / ACCESSWIRE / August 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape...
Investors In Kyverna Therapeutics Inc Are Encouraged To Assist The Schall Law Firm In A Securities Fraud Inquiry
LOS ANGELES, CA / ACCESSWIRE / August 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape...
The Schall Law Firm Is Looking Into Kyverna Therapeutics Inc For Possible Securities Law Violations And Shareholders Are Urged To Participate
LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape...
Investors With Losses In Kyverna Therapeutics Inc Are Encouraged To Join The Schall Law Firm In A Securities Fraud Investigation
LOS ANGELES, CA / ACCESSWIRE / August 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape...
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into Kyverna Therapeutics Inc For Securities Law Infractions
LOS ANGELES, CA / ACCESSWIRE / August 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape...
Kyverna Therapeutics Inc Is Being Investigated By The Schall Law Firm For Securities Fraud And Investors Are Encouraged To Contribute
LOS ANGELES, CA / ACCESSWIRE / August 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape...
The Schall Law Firm Is Looking Into Kyverna Therapeutics Inc For Potential Securities Law Violations And Impacted Shareholders Are Invited To Participate
LOS ANGELES, CA / ACCESSWIRE / August 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therape...